Estrella Immunopharma Changes Certifying Accountant
Ticker: ESLAW · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1844417
Complexity: simple
Sentiment: neutral
Topics: auditor-change, corporate-governance, 8-K
TL;DR
**Estrella Immunopharma just switched auditors, a common but noteworthy event for investors.**
AI Summary
Estrella Immunopharma, Inc. (ESLA) announced on January 30, 2024, that it is changing its independent accounting firm. This is a standard procedural update, indicating a change in the company's auditor, which is important for investors because the auditor is responsible for verifying the accuracy of the company's financial statements, impacting trust and transparency.
Why It Matters
A change in auditors can sometimes signal underlying issues, but in many cases, it's a routine business decision. Investors should monitor future filings for any further details or explanations regarding this change.
Risk Assessment
Risk Level: low — This filing only reports a change in the company's certifying accountant, which is a procedural event and does not inherently indicate high risk without further context.
Analyst Insight
Investors should note the change in auditors and look for any subsequent filings (like an NT 10-K or 10-Q) that might provide more context or disclose disagreements with the former accountant. For now, it's a procedural update.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — the registrant changing its certifying accountant
- January 30, 2024 (date) — date of earliest event reported
- TradeUP Acquisition Corp. (company) — former name of Estrella Immunopharma, Inc.
FAQ
What is the primary event reported in this 8-K filing?
The primary event reported in this 8-K filing is a change in Estrella Immunopharma, Inc.'s certifying accountant, as indicated under 'ITEM INFORMATION: Changes in Registrant's Certifying Accountant'.
When did the earliest event reported in this filing occur?
The earliest event reported in this filing occurred on January 30, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 30, 2024' section.
What is Estrella Immunopharma, Inc.'s former company name?
Estrella Immunopharma, Inc.'s former company name was TradeUP Acquisition Corp., with the date of name change being 20210204, according to the 'FORMER COMPANY' section.
What is the business address of Estrella Immunopharma, Inc.?
The business address of Estrella Immunopharma, Inc. is 5858 Horton Street, Suite 370, Emeryville, California, 94608, as listed in the 'BUSINESS ADDRESS' section.
What is the company's Standard Industrial Classification (SIC)?
Estrella Immunopharma, Inc.'s Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836], as detailed in the 'STANDARD INDUSTRIAL CLASSIFICATION' section.
Filing Stats: 970 words · 4 min read · ~3 pages · Grade level 15.1 · Accepted 2024-02-02 08:30:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
Filing Documents
- ea192700-8k_estrella.htm (8-K) — 34KB
- ea192700ex16-1_estrella.htm (EX-16.1) — 3KB
- 0001213900-24-009325.txt ( ) — 254KB
- esla-20240130.xsd (EX-101.SCH) — 4KB
- esla-20240130_def.xml (EX-101.DEF) — 26KB
- esla-20240130_lab.xml (EX-101.LAB) — 36KB
- esla-20240130_pre.xml (EX-101.PRE) — 25KB
- ea192700-8k_estrella_htm.xml (XML) — 6KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) Dismissal of Independent Registered Public Accounting Firm Estrella Immunopharma, Inc. (the "Company"), at the direction of the Board of Directors of the Company (the "Board"), and upon the recommendation of the Audit Committee of the Board, dismissed its independent registered public accountant Marcum LLP ("Marcum"), effective as of January 30, 2024. Marcum was initially engaged on November 3, 2022 by Estrella Biopharma, Inc. ("Estrella"), the Company's wholly-owned subsidiary and accounting predecessor following the consummation of the business combination between Estrella, Tradeup Merger Sub Inc. and TradeUP Acquisition Corp. on September 29, 2023, to serve as Estrella's auditor for its fiscal year ended June 30, 2023. Marcum's report on Estrella's financial or modified as to uncertainty, audit scope, or accounting principles, except that Marcum's report contained an explanatory paragraph expressing substantial doubt about the ability of Estrella to continue as a going concern. During the fiscal year ended June 30, 2023 and subsequent interim periods through the date of Marcum's dismissal, there were (i) no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, any of which, if not resolved to Marcum's satisfaction, would have caused it to make reference to the subject matter of any such disagreement in connection with its reports for such years and (ii) no "reportable events" requiring disclosure pursuant to paragraph (a)(1)(v) of Item 304 of Regulation S-K and the related instructions to Item 304 of Regulation S-K. In accordance with Item 304(a)(3) of Regulation S-K, the Company has provided Marcum a copy of the disclosures it is making in this Current Report on Form 8-K prior
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 16.1 Letter from Marcum LLP, dated February 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Dr. Cheng Liu Title: Chief Executive Officer Date: February 2, 2024 2